Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CRAT | ISIN: IT0005440893 | Ticker-Symbol: 9PC
München
17.01.25
08:09 Uhr
18,780 Euro
0,000
0,00 %
1-Jahres-Chart
WIIT SPA Chart 1 Jahr
5-Tage-Chart
WIIT SPA 5-Tage-Chart
RealtimeGeldBriefZeit
18,24019,54013:04
PR Newswire
331 Leser
Artikel bewerten:
(2)

WIIT S.p.A - Statement regarding Redcentric plc ("Redcentric")

Finanznachrichten News

PR Newswire

LONDON, United Kingdom, June 06

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE").

FOR IMMEDIATE RELEASE

Statement regarding Redcentric plc ("Redcentric")

Milan, 6 June 2024 - Further to the announcement made on 28 May 2024, WIIT S.p.A. ("WIIT"), one of the leading European players in the market of Cloud Computing services for enterprises focused on the provision of continuous Hybrid Cloud and Hosted Private Cloud services for critical applications, today confirms that it does not intend to make an offer for Redcentric.

Accordingly, WIIT (and any person acting in concert with it) is, except in the circumstances set out below or otherwise with the consent of the Panel on Takeovers and Mergers (the "Panel"), bound by the restrictions under Rule 2.8 of the City Code on Takeovers and Mergers (the "Code").

Under Note 2 on Rule 2.8 of the Code, WIIT (and any person acting in concert with it) reserves the right to set aside the restrictions in Rule 2.8 in the following circumstances:

(i) with the agreement of the board of directors of Redcentric;

(ii) following the announcement of a firm intention to make an offer for Redcentric by or on behalf of a third party;

(iii) following the announcement by Redcentric of a Rule 9 waiver proposal (as described in Note 1 of the Notes on Dispensations from Rule 9 of the Code) or a reverse takeover (as defined in the Code); or

(iv) where the Panel has determined that there has been a material change of circumstances.

* * *

WIIT S.p.A.

WIIT S.p.A., a company listed on the Euronext Star Milan ("STAR") segment, is a leader in the cloud computing market. The company has a pan-European footprint and is present in key markets such as Italy and Germany, positioning itself among the main operators in the provision of innovative Hosted Private and Hybrid Cloud technological solutions. WIIT operates its own data centers in 6 regions - 4 in Germany and 2 in Italy - of which 2 are Premium Zone-enabled, i.e. with Tier IV data centers certified by the Uptime Institute and with the highest levels of security in the design phase. WIIT has 6 SAP certifications at the highest level of specialisation. The end-to-end approach allows the company to provide partner companies with personalised services, with high added value and with the highest safety and quality standards for the management of critical applications and operational continuity, guaranteeing maximum reliability in the implementation of the main international application platforms (SAP, Oracle and Microsoft). Since 2022, the WIIT Group has joined the United Nations Global Compact. (www.wiit.cloud).

For more information

Investor Relations WIIT S.p.A.:

Stefano Pasotto - CFO & Investor Relations Director

Francesca Cocco - Lerxi Consulting - Investor Relations

T +39.02.3660.7500

Fax +39.02.3660.7505

ir@wiit.cloud

www.wiit.cloud

Media Relations:

Image Building

Rafaella Casula

T +39 348 3067877

Simona Porcino

T +39 340 9844532

Francesca Alberio

Tel. +39 340 0547370

wiit@imagebuilding.it

* * *

Important information

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise.

The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdictions.




© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.